Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores

被引:103
作者
Sato, N
Kobayashi, H
Hiraga, A
Saga, T
Togashi, K
Konishi, J
Brechbiel, MW
机构
[1] Kyoto Univ, Grad Sch Med, Chaired Dept Diagnost & Intervent Radiol, Hitachi Med Co,Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Dept Nucl Med & Diagnost Imaging, Kyoto 6110011, Japan
[3] NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA
关键词
magnetic resonance imaging; pharmacokinetics; macromolecule; MR contrast agent; dendrimer;
D O I
10.1002/mrm.1314
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Four macromolecular contrast agents are synthesized to visualize small vessels by MRI using generation-3 (G3D), -4 (G4D), -5 (G5D), and -6 (G6D) polyamidoamine dendrimers conjugated to chelated gadolinium (Gd). The pharmacokinetics, enhancement patterns, and the ability of these constructs to visualize fine vessels is evaluated by dynamic MRI in relationship to their size. Gd-G6D and -G5D exhibit a prolonged high vascular (ventricular) signal intensity (SI) with high ventricle-to-organ SI ratios. The initial high vascular SI with Gd-G4D decreases to a value as low as that obtained with Gid-G3D and Gd-dimeglumine-diethylenetriaminepentaacetic acid (Gd-DTPA). Gd-G5D, -G4D, and -G3D show high renal Isis, and Gd-DTPA prominently enhances the skin. Gd-G6D and -G5D present fine vasculature significantly more clearly than Gd-G3D and -DTPA (P < 0.005). As the molecular size increases, the excretion of the Gd-153-conjugates is retarded. In conclusion, Gd-G6D and -G5D are retained in the blood and present fine vessels with high quality and detail, and should be adequate for visualizing small tumor vasculature. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:1169 / 1173
页数:5
相关论文
共 17 条
[1]   MAGNETIC-RESONANCE-IMAGING DETECTION OF AN EXPERIMENTAL PULMONARY PERFUSION DEFICIT USING A MACROMOLECULAR CONTRAST AGENT - POLYLYSINE-GADOLINIUM-DTPA(40) [J].
BERTHEZENE, Y ;
VEXLER, V ;
PRICE, DC ;
WISNERDUPON, J ;
MOSELEY, ME ;
AICHER, KP ;
BRASCH, RC .
INVESTIGATIVE RADIOLOGY, 1992, 27 (05) :346-351
[2]   A NEW MACROMOLECULE AS A CONTRAST AGENT FOR MR-ANGIOGRAPHY - PREPARATION, PROPERTIES, AND ANIMAL STUDIES [J].
BOGDANOV, AA ;
WEISSLEDER, R ;
FRANK, HW ;
BOGDANOVA, AV ;
NOSSIF, N ;
SCHAFFER, BK ;
TSAI, E ;
PAPISOV, MI ;
BRADY, TJ .
RADIOLOGY, 1993, 187 (03) :701-706
[3]   Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body [J].
Bourne, MW ;
Margerun, L ;
Hylton, N ;
Campion, B ;
Lai, JJ ;
Derugin, N ;
Higgins, CB .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1996, 6 (02) :305-310
[4]   Assessing tumor angiogenesis using macromolecular MR imaging contrast media [J].
Brasch, R ;
Pham, C ;
Shames, D ;
Roberts, T ;
vanDijke, K ;
vanBruggen, N ;
Mann, J ;
Ostrowitzki, S ;
Melnyk, O .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (01) :68-74
[5]  
Carrasquillo JA, 1998, CANCER RES, V58, P2612
[6]  
DEPALATIS LR, 1995, CANCER RES, V55, P5288
[7]   Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine [J].
Kobayashi, H ;
Sato, N ;
Kawamoto, S ;
Saga, T ;
Hiraga, A ;
Ishimori, T ;
Konishi, J ;
Togashi, K ;
Brechbiel, MW .
MAGNETIC RESONANCE IN MEDICINE, 2001, 46 (03) :457-464
[8]  
Kobayashi H, 1996, CANCER RES, V56, P3788
[9]  
Kobayashi H, 2001, MAGNET RESON MED, V45, P454, DOI 10.1002/1522-2594(200103)45:3<454::AID-MRM1060>3.0.CO
[10]  
2-M